Bhamarapravati N, Yoksan S, Chayaniyayothin T, Angsubphakorn S, Bunyaratvej A
Bull World Health Organ. 1987;65(2):189-95.
A live dengue-2 (DEN-2) candidate vaccine (strain 16681-PDK 53), attenuated by passage in primary dog kidney cells, was tested in ten adult volunteers for evaluation of the safety, infectivity and immunogenicity of a dose of 1.9-2.7 x 10(4) plaque-forming units. Five of the volunteers were nonimmune to either dengue or Japanese encephalitis (JE) viruses; the other five were nonimmune to dengue but immune to JE. After receiving 1.0 ml of the vaccine subcutaneously, all ten volunteers developed neutralizing antibodies to DEN-2 which were maintained for at least one and a half years. None of the subjects developed abnormal signs or symptoms and the results of clinical chemistry investigations were within normal range throughout the 21 days of observation after the immunization. Virus isolated from one viraemic volunteer retained the small-plaque and temperature-sensitive growth characteristics of the vaccine virus in vitro. Further testing of this candidate vaccine in humans is indicated.
一种通过在原代犬肾细胞中传代减毒的登革2型（DEN-2）候选疫苗（16681-PDK 53株），以1.9 - 2.7×10⁴蚀斑形成单位的剂量，在10名成年志愿者身上进行了安全性、感染性和免疫原性评估测试。其中5名志愿者对登革病毒和日本脑炎（JE）病毒均无免疫力；另外5名对登革病毒无免疫力，但对JE病毒有免疫力。皮下注射1.0毫升疫苗后，所有10名志愿者均产生了针对DEN-2的中和抗体，且至少维持了一年半。在免疫后的21天观察期内，所有受试者均未出现异常体征或症状，临床化学检查结果也均在正常范围内。从一名病毒血症志愿者身上分离出的病毒在体外保留了疫苗病毒的小蚀斑和温度敏感生长特性。表明该候选疫苗需要在人体中进行进一步测试。
